NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE · Biotechnology · USD

Arcus Biosciences, Inc. (RCUS) Stock Analysis

Arcus Biosciences, Inc. (RCUS) is a Biotechnology stock listed on NYSE and quoted in US Dollar.

Last Updated: October 21, 2026

RCUS

$19.10

−$4.65 (−19.58%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RCUS with… →

RCUS Key Statistics

As of Oct 21, 2026
Trading
Open
$24.47
Previous Close
$23.75
Day's Range
18.98–24.35
52-Week Range
16.41–31.74
Volume
4.51M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.94
Valuation
Market Cap
$2.40B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
20.53
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.91
Financials (FY)
Revenue (FY)
$247.00M−4.26%
Net Income (FY)
−$353.00M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
125.77M
1-Year Return
+5.82%
Dividend and dates
Earnings Date
October 27, 2026
Avg Volume
1.49M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, RCUS closed at $19.10, +5.82% over 1 year.

Arcus Biosciences, Inc. (RCUS) has a market capitalization of $2.40B.

In fiscal 2025, RCUS reported revenue of $247.00M.

RCUS Stock Return by Calendar Year

Arcus Biosciences, Inc. (RCUS) return since Mar 2018: what $10,000 became

1 year
$10,000 $10,582
+5.82%
5 years
$10,000 $5,449
−45.51%
Since Mar 2018
$10,000 $11,235
+12.35%

If you had invested $10,000 in Arcus Biosciences, Inc. (RCUS) at the close on March 15, 2018, the earliest close on record here, it would have been worth $11,235 at the close on October 21, 2026: +12.35% in total, +1.36% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−19.85%
2025+60.04%
2024−22.04%
2023−7.64%
2022−48.90%
2021+55.89%
2020+157.03%
2019−6.22%
2018 (partial year)−36.65%

As of October 21, 2026.

RCUS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$247.00M−$353.00M−142.9%
2024$258.00M−$283.00M−109.7%
2023$117.00M−$307.00M−262.4%
2022$112.00M−$267.00M−238.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$247.00M—−$386.00M−$353.00M−142.9%
2024$258.00M—−$310.00M−$283.00M−109.7%
2023$117.00M—−$340.00M−$307.00M−262.4%
2022$112.00M—−$280.00M−$267.00M−238.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RCUS Valuation vs Biotechnology Median

Median of 608 stocks
MetricRCUSBiotechnology medianvs median
P/S ratio20.5313.3054% above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Arcus Biosciences, Inc. (RCUS) is capitalised at $2.40B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 601 employees.

The 52-week range on file runs from $16.41 to $31.74. RCUS last closed at $19.10 on October 21, 2026. That is −$4.65 (−19.58%) against the previous close. The latest close sits 16.39% above that 52-week low.

Financial Health

In fiscal 2025, Arcus Biosciences, Inc. reported revenue of $247.00M. Against the prior fiscal year total of $258.00M, that is a change of −4.26%. The same year closed with a net loss of $353.00M. Trailing earnings per share are −3.91.

Across the 4 fiscal years on file, revenue moves from $112.00M in 2022 to $247.00M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 20.53 times revenue. On price-to-sales that is 54.39% above the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.94. Annualized volatility over the trailing 8 years is 77.08%. The trailing one-year total return is +5.82%. Across 5 years the annualized return works out at −11.43%.

Growth & Income

The record shows no dividend for RCUS.

2026 is still running; the total return is −19.85% year to date. The strongest complete calendar year on file is 2020 at +157.03%; the weakest is 2022 at −48.90%. Of the 7 complete calendar years on file, 3 finished higher.

Peer Comparison

Arcus Biosciences, Inc. (RCUS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Arcus Biosciences, Inc. RCUS $2.40B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Arcus Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Arcus Biosciences, Inc.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Visit website →